CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The NABARSI project aims to discover new antibacterial compounds to combat multi-drug resistant bacterial infections. By targeting essential enzymes in bacteria, it seeks to develop broad-spectrum antibiotics that can overcome existing resistance mechanisms.
The NABARSI consortium will develop a cutting-edge drug discovery project to increase the antibacterial pipeline.
The main goal of NABARSI is to find new chemical entities (NCEs) with antibacterial efficacy in animal models of multi-drug resistant (MDR) bacterial infection and to exploit the results through obtaining a co-development with industry.
The NABARSI consortium consists of 5 partners:
Omnia Molecular (Omnia, SME;
Spain).
InhibOx (SME, UK).
Latvian Institute of Organic Synthesis (LIOS,…
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, LONDON
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, Leeds
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, BARCELONA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
